Gilles Tamagnan, PhD - Chief Executive Officer
Dr. Tamagnan is an Associate Professor Adjunct, Department of Psychiatry, and the CEO of XingImaging and Research Scientist at Xuanwu Hospital in Beijing. Dr. Tamagnan provides leadership and expert knowledge to colleagues to design and coordinate experiments for radiolabeling the tracers and for developing them into a radiopharmaceutical suitable for human administration. He is also responsible of the IND submission and working with the clinical team to validate the radiopharmaceutical. He has over 20 years of industrial and academic experience in the research and development of radiopharmaceuticals labeled with short-lived gamma-emitting radionuclides. Dr. Tamagnan is an active member of the nuclear medicine research community over the past 20 years and has been involved in the evaluation of over 70 CNS PET and SPECT imaging agents in human aimed at the development of improved diagnosis and treatment of neurologic and psychiatric conditions. He is a physician sponsor of over 35 INDs.
Roger Gunn, PhD - Chief Science Officer
Dr. Gunn is an Emeritus Professor of Molecular Neuroimaging in the Division of Brain Sciences at Imperial College London and CSO of XingImaging. Dr. Gunn is an international expert on imaging for disease understanding and drug development. He has combined a career in academia (McGill University, Oxford University and Imperial College) and industry (GSK, Imanova, Invicro and XingImaging) holding Chief Science Officer positions for the last 15 years with responsibility for large scientific imaging portfolios. He has published over 200 peer reviewed papers in the field of imaging and drug development with an H-index of 75 and has delivered over 80 invited lectures. His career has involved positions on research councils, consultancy to pharmaceutical companies and the training and mentoring of PhD students and clinical research fellows. As Chief Science Officer at XingImaging he is heading the companies R&D of new biomarkers & analytics and leading the design, analysis and delivery of preclinical & clinical imaging trials for pharmaceutical companies .
Rebecca Evans, JD - General Manager - US Operations
In 2023, Rebecca took on the role of General Manager, US Operations after serving as the COO of XingImaging since 2019. Prior to that she worked for more than 15 years with XingImaging’s principals and lead scientists at Molecular NeuroImaging (MNI) and the Institute for Neurodegenerative Disorders (IND). During her time at MNI and IND Rebecca helped build the companies’ regulatory affairs and quality groups, developing policies and procedures, company structure with business awareness and regulatory rigor. During the second half of her time with these organizations, she headed up operations which where she honed her experience with contract and budget review and approval, company system oversight, business development, and team management. Rebecca is a licensed attorney in the State of Connecticut, US.
Zhuqin (Kitty) Gu, MD PhD - General Manager & Director Operations - China
Dr. Gu has over 15 years of experience in clinical studies on early prediction and management of Parkinson's disease. She worked as project manager for multiple national and international cooperation projects, including MJFF projects, and played an important role in the setup and management for the first clinical center and specialist training system on Parkinson’s disease & Movement disorders in China. In 2018, Dr. Gu joined XingImaging China, started to build up the National PET network in China, and set up the standardized SOP for clinical operations for PET studies.
Scientific Advisors
Piu (Bill) Chan, M.D. Ph.D.
Dr. Chan is well known for his translational research on neurodegenerative disorders and other age-related disorders. Collaborating with Dr. Carlie Tanner on several unique cohorts, they were the first reporting that environmental exposures are the major risk factors for Parkinson’s disease. He has worked on developing models for CNS diseases including non-human primate models of Parkinson’s disease and dyskinesia. He has been studying familial and susceptibility genes and a variety of biomarkers for Parkinson's and Alzheimer's diseases in a few unique cohorts in China aimed for prediction and prevention of neurodegenerative diseases. Dr. Chan is the committee member for the MDS “Task Force on the definition of Parkinson’s disease” and “Telemedicine Task Force”. Dr. Chan’s team has participated in the International LRRK2 Consortium and Apple’s mPower projects. Dr. Chan has published more than 240 SCI peer-reviewed papers and about 350 peer-reviewed Chinese papers and served as editorial members of more than 15 international and Chinese journals.
Kenneth Marek, M.D.
Dr. Marek is a neurologist with widespread expertise in neurodegenerative disorders. He is internationally recognized as an expert in imaging of neurodegenerative disorders and has made significant contributions to early detection and diagnostic use of radiotracers for these disorders for PD, AD, HD and other disorders. He has developed novel clinical design for brain imaging studies and has been the Principal Investigator in several multicenter trials including PPMI and PARS.
John Seibyl, M.D.
Dr. Seibyl is an international expert on PET and SPECT imaging for neurodegenerative disorders. He is past President of the Brain Imaging Council of the Society of Nuclear Medicine. Dr. Seibyl is dually-boarded in Nuclear Medicine and Psychiatry and has twenty years of experience in clinical studies. He has made significant contributions to development of visual and quantitative analysis for PET imaging in neurodegenerative and neuropsychiatric disorders. Along with Dr. Marek he has directed and continues to direct several international multicenter imaging studies. Dr. Seibyl is an author on over one hundred publications on CNS imaging.
